Connect with us

Health

Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment Landscape – Targeted Oncology

While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients…

Published

on

Article feature image

While the treatment of relapsed or refractory (R/R) Hodgkin lymphoma (HL) has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.1
Two studies presented during the 62nd American Society of Hematology Annual Meeting and Exposition explored new therapeutic strategies for this patient population. First, results from a phase 2 study (NCT04052997) suggest that camidanlumab tesirine (ADCT-301) can…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
‘Raging inferno’: Worldwide COVID-19 death toll tops a staggering 3 million – Sydney Morning Herald
Vaccine immunity ‘won’t just disappear’ in face of Covid variants – JCVI expert – Yahoo Movies UK